ReviewClinical Medicine Insights. Oncology2025
Research Progress of LEF1 Gene in Malignant Tumors.
Review in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, one of the most dynamic and rapidly advancing areas in biomedical research is the study of cell signaling systems. In particular, researchers have directed significant attention toward the Wnt signaling pathway, which has emerged as a critical player in several biological processes, including embryonic development, cancer progression, and the maintenance of tissue homeostasis. The growing body of research demonstrating the Wnt pathway's critical functions in various activities emphasizes the pathway's importance. Lymphoid enhancer factor-1 (LEF-1) is a crucial component of the Wnt signaling cascade, among its numerous components. The β-catenin/LEF complex, which is essential for triggering transcriptional responses, is formed when the N-terminal domain of LEF-1 binds with β-catenin. This complex acts as a central "activation hub" within the Wnt pathway, integrating signals from β-catenin and LEF-1 to facilitate gene expression that is critical for cellular functions. This narrative review focuses on highlighting the latest advancements in LEF-1 research, particularly its role in cancer. By emphasizing the significance of LEF-1 in the processes of carcinogenesis, the discussion aims to shed light on the potential implications of these findings for developing innovative treatment strategies. Understanding the function of LEF-1 not only enhances our comprehension of tumor biology but also opens pathways to novel therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.